These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 2112648)

  • 1. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters.
    Atkinson JB; Bagnall HA; Gomperts E
    JPEN J Parenter Enteral Nutr; 1990; 14(3):310-1. PubMed ID: 2112648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial.
    Haire WD; Atkinson JB; Stephens LC; Kotulak GD
    Thromb Haemost; 1994 Oct; 72(4):543-7. PubMed ID: 7878629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis in infants and children.
    Bagnall HA; Gomperts E; Atkinson JB
    Pediatrics; 1989 Jun; 83(6):963-6. PubMed ID: 2657625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters.
    Chesler L; Feusner JH
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):653-6. PubMed ID: 12439038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of tissue plasminogen activator for thrombolysis in occluded peritoneal dialysis catheters in children.
    Shea M; Hmiel SP; Beck AM
    Adv Perit Dial; 2001; 17():249-52. PubMed ID: 11510286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator.
    Rodenhuis S; van't Hek LG; Vlasveld LT; Kröger R; Dubbelman R; van Tol RG
    Thorax; 1993 May; 48(5):558-9. PubMed ID: 8322245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review.
    Clase CM; Crowther MA; Ingram AJ; Cinà CS
    J Thromb Thrombolysis; 2001 Apr; 11(2):127-36. PubMed ID: 11406727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of thrombolytic therapy for occlusion of long-term catheters.
    Monturo CA; Dickerson RN; Mullen JL
    JPEN J Parenter Enteral Nutr; 1990; 14(3):312-4. PubMed ID: 2112649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the removal of a central venous catheter always necessary in the context of catheter-related right atrial thrombosis?
    Rossi L; Libutti P; Casucci F; Lisi P; Teutonico A; Basile C; Lomonte C
    J Vasc Access; 2019 Jan; 20(1):98-101. PubMed ID: 29749281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteplase versus urokinase for occluded hemodialysis catheters.
    Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
    Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of flow following haemodialysis catheter thrombus. Analysis of rt-PA infusion in tunnelled dialysis catheters.
    Davies J; Casey J; Li C; Crowe AV; McClelland P
    J Clin Pharm Ther; 2004 Dec; 29(6):517-20. PubMed ID: 15584939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of obstruction and thrombosis due to central venous catheterization].
    Leititis JU
    Klin Padiatr; 1991; 203(6):420-3. PubMed ID: 1758144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of rt-PA infusion in tunnelled dialysis catheters.
    Davies J; Casey J; Li C; Crowe AV; McClelland P
    EDTNA ERCA J; 2005; 31(2):75-8. PubMed ID: 16180551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
    Jacobs BR; Haygood M; Hingl J
    J Pediatr; 2001 Oct; 139(4):593-6. PubMed ID: 11598611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Audit to Study urokinaSe use to restore Patency in Occluded centRal venous caTheters (PASSPORT 1).
    Kumwenda MJ; Mitra S; Khawaja A; Inston N; Nightingale P
    J Vasc Access; 2019 Nov; 20(6):752-759. PubMed ID: 31466489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
    Pollo V; Dionízio D; Bucuvic EM; Castro JH; Ponce D
    Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombosed central venous catheters: restoring function with 6-hour urokinase infusion after failure of bolus urokinase.
    Haire WD; Lieberman RP
    JPEN J Parenter Enteral Nutr; 1992; 16(2):129-32. PubMed ID: 1556806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of tissue plasminogen activator for reopening of clotted dialysis catheters.
    Paulsen D; Reisoether A; Aasen M; Fauchald P
    Nephron; 1993; 64(3):468-70. PubMed ID: 8341396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.